Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2023 12:50 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Announces Reverse Stock Split

MIAMI, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
October 05, 2023 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference

Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.
September 07, 2023 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference

MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
August 14, 2023 16:01 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials...
August 03, 2023 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023

MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
June 29, 2023 08:00 ET | Source: Fortress Biotech, Inc.

Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States

Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese healthy subjects Initiating Phase 1b clinical...
June 15, 2023 08:00 ET | Source: Fortress Biotech, Inc.

Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program

Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk...
May 15, 2023 16:01 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic...
April 24, 2023 08:00 ET | Source: Fortress Biotech, Inc.

Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H

MIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, and 4D Molecular Therapeutics (Nasdaq:...
March 30, 2023 16:10 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application...